Beractant is used for the prevention or rescue treatment of hyaline membrane disease (respiratory distress syndrome [RDS]) in premature neonates.

Beractant is an exogenous pulmonary surfactant preparation. Beractant is a lung surface acting agent, or "surfactant." It helps the lungs function normally. Beractant is similar to the natural fluid in the lungs that helps maintain effective breathing.

There are no contraindications listed in the manufacturer's labeling.

Unknown

Unknown

pale skin; slow heartbeat; breathing that stops; urinating less than usual; or blood in the urine.

Prevention of RDS in infants less than 1250 g birth weight: 100 mg/kg birth weight intratracheally, preferably within 15 minutes of birth. Treatment (rescue) of RDS: 100 mg/kg birth weight intratracheally, preferably by 8 hours of age. Maintenance dose: Doses of 100 mg/kg birth weight can be repeated every 6 hours. Maximum dose: Total of 4 doses within 48 hours of life.